[PAGID] XLP testing - NK function results

[Tamara Pozos]

NK testing results done in Cincinanati lab: overall normal

lytic units 7.2 (>3.1)
CD16/56%+  10% (4-26%)

dilution%     cytotoxicity   ref.
6:1              5%             >1
12:1            8%             >5
25:1            13%          >10
50:1            20%          >20



Tamara Pozos, MD PhD
Pediatric Infectious Diseases and Immunology 
Children's Hospitals and Clinics of Minnesota 
Mail Stop 70-504 
Garden View Building, 3rd Floor 
345 Smith Avenue North 
St. Paul, MN  55102 
tamara.pozos at childrensmn.org 
651-220-6444 (office)



>>> "Junker, Anne" <ajunker at cw.bc.ca> 8/24/2009 3:07 PM >>>


 Tamara - the scanned reports didn't come through.  What NK function
assays were done and have you studied for presence or function of NK-T
cells? I copy Dr. Rusung Tan at our centre, who is a leading
investigator in this field.
Anne

 
Anne K. Junker, MD
Associate Professor, Division of Infectious & Immunological Diseases
Director, Clinical and Population Health Studies, Child & Family
Research Institute
BC Children's and University of British Columbia
Director, Mother Infant Child Youth Research Network -Reseau de
Recherche en Sante des Enfants et des Meres
Vancouver, BC  V6H 3V4
Ph: 604-875-3519   Fx: 604-875-2414


-----Original Message-----
From: pagid-bounces at list.clinimmsoc.org 
[mailto:pagid-bounces at list.clinimmsoc.org] On Behalf Of Tamara Pozos
Sent: Monday, August 24, 2009 12:35 PM
To: pagid at list.clinimmsoc.org 
Subject: [PAGID] XLP testing

Hello all - I am writing for advice re: genetic testing for severe
EBV/XLP-like illness - (brother of my patient had a similar syndrome at
22 months, and there is a 3rd unaffected brother).  Specifically, are
there other tests in addition to SH2D1A, (also ?XIAP) and if there is
one particular lab that is recommended for this testing? Any other
suggestions?

Clinical story in brief: previously well 6 year old boy with rapid onset
of high fever, massive hepatosplenomegaly, nephritis, pleural effusions
severe enough that PICU for respiratory concerns.  Multiple IgMs to
viruses/Mycoplasma were positive,  so when I met him I sent PCRs: EBV
95K,CMV neg. Heme/onc also involved for concern of HLH, no lymph node or
bone marrow biopsies were done.  Given concerns of rapid progression, I
treated him a few days with gancyclovir and he improved rapidly.
Followup EBV level was 1500, stopped GCV.  One the day of discharge, he
developed disseminated rash that very much resembled the amox rash seen
with mono.

When I saw him last week in followup, rash was nearly faded, HSM and LAD
had resolved.  I rechecked viral load and it rebounded somewhat, total
CD3# continues to increase, Bcells lower so I am presuming that it's
Bcell EBV tropism in this case.  Kid continues afebrile and to feel
well.

The affected brother was 22 months when he went through this, also
developed a rash in the recovery stage, and is now 9 years old. 

Thanks so much! Patient is coming back to see me in a few days.
Tamara Pozos, MD PhD



Details of labs, if one is interested. 
7/29/09
 	VCA Aby- IgG NEGATIVE
 	VCA Aby- IgM POSITIVE
 	EBNA Aby NEGATIVE &
 	CMV IgG NEGATIVE &
 	CMV IgM POSITIVE &
 	
 08/01/09 07:00 	
 	Ferritin 429 ng/mL (H) (Ref. Range 7 - 142)
 	Interleukin-2 Receptor >6500 U/mL & (H)

 08/02/09 20:30 		
 	Triglycerides 136 mg/dL (H) (Ref. Range 0 - 103)

 08/03/09 08:29 	
 	CD3+ Absolute 3,897 /uL (H) (Ref. Range 700 - 2,900)
 	CD4+/CD3+ Absolute 906 /uL (Ref. Range 400 - 1,500)
 	CD8+/CD3+ Absolute 2,723 /uL (H) (Ref. Range 180 - 1,000)
 	CD19+ Absolute 309 /uL (Ref. Range 200 - 800)
 	CD16+56+/CD3- Absolute 417 /uL (Ref. Range 100 - 800)
 	CD4:CD8 Ratio 0.33 (L) (Ref. Range 0.83 - 2.19)
 
 EBV Copies per mL 92,000
 	
 08/03/09 11:35 	
 	NK Function See Comments &
 	Chemistry Reports- scanned Chemistry Reports- scanned
  
 	IgM 182.0 mg/dL & (Ref. Range 46 - 197)
 	IgA 138.0 mg/dL & (Ref. Range 33 - 234)
 	IgG Subclass 1 1,009 mg/dL & (H) (Ref. Range 292 - 816)
 	IgG Subclass 2 126 mg/dL & (Ref. Range 83 - 513)
 	IgG Subclass 3 74 mg/dL & (Ref. Range 8 - 111)
 	IgG Subclass 4 51 mg/dL & (Ref. Range 1 - 121)
 	IgG 1,260 mg/dL & (H) (Ref. Range 608 - 1,229)
 	IgE 402.0 IU/mL & (H) (Ref. Range 0 - 90)

 	Ferritin 1,334 ng/mL (H) (Ref. Range 7 - 142)
  

 08/04/09 19:08 	
 	CMV by PCR- CMPC None Detected &

 08/07/09 08:16 	
 	Ferritin 1,400 ng/mL (H) (Ref. Range 7 - 142)
 
 	EBV Copies per mL 1,500 &
 Gancyclovir stopped	
  
Discharged home with rash developing, fever resolved after rash peaked.

Seen in followup 08/10/09, clinically very well 	
 	CD3+ Absolute 6,541 /uL (H) (Ref. Range 700 - 2,900)
 	CD4+/CD3+ Absolute 2,109 /uL (H) (Ref. Range 400 - 1,500)
 	CD8+/CD3+ Absolute 4,080 /uL (H) (Ref. Range 180 - 1,000)
 	CD19+ Absolute 100 /uL (L) (Ref. Range 200 - 800)
 	CD16+56+/CD3- Absolute 1,142 /uL (H) (Ref. Range 100 - 800)
 	CD4:CD8 Ratio 0.52 (L) (Ref. Range 0.83 - 2.19)
 
 	EBV Copies per mL 5,500
 	


Tamara Pozos, MD PhD
Pediatric Infectious Diseases and Immunology 
Children's Hospitals and Clinics of Minnesota 
Mail Stop 70-504 
Garden View Building, 3rd Floor 
345 Smith Avenue North 
St. Paul, MN  55102 
tamara.pozos at childrensmn.org 
651-220-6444 (office)
651-220-6293 (desk/voicemail)
612-589-7976 (pager)


_______________________________________________________________

Confidentiality Statement:
This email/fax, including attachments, may include confidential
and/or proprietary information and may be used only by the
person or entity to which it is addressed. If the reader of 
this email/fax is not the intended recipient or his or her 
agent, the reader is hereby notified that any dissemination, 
distribution or copying of this email/fax is prohibited. If you 
have received this email/fax in error, please notify the sender 
by replying to this message and deleting this email or 
destroying this facsimile immediately.


_______________________________________________________________

Confidentiality Statement:
This email/fax, including attachments, may include confidential
and/or proprietary information and may be used only by the
person or entity to which it is addressed. If the reader of 
this email/fax is not the intended recipient or his or her 
agent, the reader is hereby notified that any dissemination, 
distribution or copying of this email/fax is prohibited. If you 
have received this email/fax in error, please notify the sender 
by replying to this message and deleting this email or 
destroying this facsimile immediately.